A universal chimeric antigen receptor (CAR)–fragment antibody binder (FAB) split system for cancer immunotherapy
Science Advances · 04.07.2025 · 11 (27)
DOI: 10.1126/sciadv.adv4937 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 04.07.2025. Verfasst von Ainhoa Arina und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Immunoglobulin Fab Fragments, Immunotherapy, Adoptive, Immunotherapy. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) T cell therapy has shown extraordinary results in treating hematological cancer but faces challenges like antigen loss, toxicity, and complex manufacturing. Universal and modular CAR constructs offer improved flexibility, safety, and cost-effectiveness over conventional CAR constructs. We present a CAR–fragment antibody binder (Fab) platform on the basis of an engineered protein G variant (GA1) and Fab scaffolds. Expression of GA1CAR on human CD8 + T cells leads to antigen recognition and T cell effector function that can be modulated according to the affinity of the CAR for the Fab and of the Fab for the target. GA1CAR T cells can recognize multiple Fab-antigen pairs on breast and ovarian cancer cell lines. Adoptively transferred GA1CAR T cells control tumors in breast cancer xenograft models, and their targeting can be quickly redirected using different Fabs. This versatile “plug-and-play” CAR T platform has potential for application in personalized therapy, preventing antigen loss variant escape, decreasing toxicity, and increasing access.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation and Cellular Oncology and Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL, USA.
- Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, USA.
- Jagiellonian University, Kraków, Poland.
- Warsaw University of Technology, Warsaw, Poland.
- University of Warsaw, Warsaw, Poland.
- Silesian University of Technology, Gliwice, Poland.
ORCID-Profile: Ainhoa Arina, Karolina W Warzecha, Annika Sääf, Tomasz Slezak, Aleksandra Zieminska, Karolina Dudek, Maria Lecka, Svitlana Usatyuk, Ralph R Weichselbaum, Anthony A Kossiakoff
Förderung
- NIGMS NIH HHS
Zitieren
APA
Arina, A., Arauz, E., Masoumi, E., Warzecha, K. W., Sääf, A., Widło, Ł., Slezak, T., Zieminska, A., Dudek, K., Schaefer, Z. P., Lecka, M., Usatyuk, S., Weichselbaum, R. R., & Kossiakoff, A. A. (2025). A universal chimeric antigen receptor (CAR)–fragment antibody binder (FAB) split system for cancer immunotherapy. Science Advances, 11(27). https://doi.org/10.1126/sciadv.adv4937
Vancouver
Arina A, Arauz E, Masoumi E, Warzecha KW, Sääf A, Widło Ł, et al. A universal chimeric antigen receptor (CAR)–fragment antibody binder (FAB) split system for cancer immunotherapy. Science Advances. 2025;11(27). doi:10.1126/sciadv.adv4937
BibTeX
@article{Arina2025,
author = {Arina, Ainhoa and Arauz, Edwin and Masoumi, Elham and Warzecha, Karolina W and Sääf, Annika and Widło, Łukasz and Slezak, Tomasz and Zieminska, Aleksandra and Dudek, Karolina and Schaefer, Zachary P and Lecka, Maria and Usatyuk, Svitlana and Weichselbaum, Ralph R and Kossiakoff, Anthony A},
title = {A universal chimeric antigen receptor (CAR)–fragment antibody binder (FAB) split system for cancer immunotherapy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {27},
doi = {10.1126/sciadv.adv4937}
}
EUVIMED